- Trials with a EudraCT protocol (12)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
12 result(s) found for: Vitamin K deficiency.
Displaying page 1 of 1.
EudraCT Number: 2019-004906-88 | Sponsor Protocol Number: NL69395.042.19 | Start Date*: 2020-04-24 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Placebo-controlled double-blind randomized controlled trial investigating vitamin K supplementation on vascular calcification propensity in vitamin K deficient renal transplant recipients | ||
Medical condition: Vitamin K deficiency is highly prevalent among renal transplant recipients, promotes vascular calcification, and is associated with an increased risk of cardiovascular disease. Supplementation of ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-002387-33 | Sponsor Protocol Number: VitalD | Start Date*: 2008-06-03 | |||||||||||
Sponsor Name:Hôpital Erasme | |||||||||||||
Full Title: Impact of 25-hydroxy vitamin D deficiency and its correction on mineral and bone disorde among hemodialysis patients | |||||||||||||
Medical condition: 25-OH vitamin D deficiency and mineral - bone disorder in hemodialysis patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019250-41 | Sponsor Protocol Number: 220901 | Start Date*: 2010-05-27 | |||||||||||
Sponsor Name:Baxter Innovations GmbH | |||||||||||||
Full Title: AN INTERNATIONAL, MULTI-CENTRE, PROSPECTIVE, OPEN-LABEL, NON-RANDOMISED, UNCONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROTHROMPLEX TOTAL IN ORAL ANTICOAGULANT REVERSAL IN PATIENTS WITH A... | |||||||||||||
Medical condition: Acquired Deficiency of Prothrombin Complex Coagulation Factors (II, VII, IX, X) due to oral anticoagulant therapy with Vitamin K antagonists | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000945-20 | Sponsor Protocol Number: vitk2006 | Start Date*: 2006-08-22 | |||||||||||
Sponsor Name:Barts and the London NHS Trust | |||||||||||||
Full Title: To investigate the effect of vitamin K supplementation on markers of bone turnover and bone density in adolescents and adults with cystic fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003858-85 | Sponsor Protocol Number: HFIRONT | Start Date*: 2020-02-24 |
Sponsor Name:Medical University Innsbruck | ||
Full Title: Randomized double-blind explorative controlled clinical trial analyzing the effects of ferric carboxymaltose in patients with iron deficiency and chronic heart failure | ||
Medical condition: This is a randomized double-blind explorative controlled clinical Trial that analyses the effects of 1000mg ferric carboxymaltose in patients with chronic heart failure and iron deficiency. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-007862-39 | Sponsor Protocol Number: BE1116_3003 | Start Date*: 2009-01-16 | ||||||||||||||||
Sponsor Name:CSL Behring GmbH | ||||||||||||||||||
Full Title: An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by vitamin K an... | ||||||||||||||||||
Medical condition: Perioperative prophylaxis for emergency surgery in subjects who have an acquired deficiency of vitamin K-dependent coagulation factors and proteins C and S | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000202-37 | Sponsor Protocol Number: BUR02 | Start Date*: 2018-10-09 | |||||||||||
Sponsor Name:Kyowa Kirin Pharmaceutical Development Ltd | |||||||||||||
Full Title: A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) | |||||||||||||
Medical condition: XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. This genetic deficiency is estimated to occur in about 1:20,000 live births (Burn... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000469-19 | Sponsor Protocol Number: BUR-CL207 | Start Date*: 2020-11-03 | |||||||||||
Sponsor Name:Kyowa Kirin Pharmaceutical Development Ltd. | |||||||||||||
Full Title: A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Ag... | |||||||||||||
Medical condition: XLH is a rare, genetic disorder that is serious, chronically debilitating and represents an unmet medical need. This genetic deficiency is estimated to occur in about 1:20,000 live births (Burnett ... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Prematurely Ended) SE (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007861-19 | Sponsor Protocol Number: BE1116_3002 | Start Date*: 2009-01-16 | ||||||||||||||||
Sponsor Name:CSL Behring GmbH | ||||||||||||||||||
Full Title: An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by coumarin der... | ||||||||||||||||||
Medical condition: Therapy of major bleeding resulting from an acquired deficiency of vitamin K-dependent coagulation factors and proteins C and S due to use of oral anticoagulation therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021179-10 | Sponsor Protocol Number: TRO19622 CLEQ 1425-1 | Start Date*: 2011-03-15 | |||||||||||
Sponsor Name:TROPHOS SA | |||||||||||||
Full Title: An Open-Label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004287-30 | Sponsor Protocol Number: LAL-CL06 | Start Date*: 2014-06-19 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals inc | |||||||||||||
Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency | |||||||||||||
Medical condition: Lysosomal Acid Lipase Deficiency (LALD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005186-18 | Sponsor Protocol Number: S187.3.004 | Start Date*: 2007-11-16 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals B.V. | |||||||||||||
Full Title: Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations | |||||||||||||
Medical condition: Treatment of levodopa-responsive Parkinson's subjects with severe motor fluctuations. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PT (Completed) IT (Completed) CZ (Completed) ES (Completed) NL (Completed) GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
